Table 3.
Incidence of leukopenia and neutropenia per schedule according to different age intervals
| Combination (TAC) schedule (n = 450) | Sequence schedule (n = 360) | Combination dose-dense (ATdd) schedule (n = 121) | Sequence dose-dense schedule (n = 86) | |||
| Nontaxane | Taxane | Nontaxane (dose-dense epirubicin) | Taxane (dose-dense paclitaxel) | |||
| Leukopenia | ||||||
| Patients aged < 60 years | 878 (57.3) | 423 (43.4) | 419 (47.3) | 164 (50.2) | 82 (29.2) | 7 (2.6) |
| Patients aged 60 to 64 years | 175 (65.3) | 124 (53.9) | 107 (51.0) | 49 (61.3) | 20 (36.4) | 0 (0.0) |
| Patients aged > 64 years | 111 (64.9) | 99 (60.7) | 71 (49.0) | 25 (62.5) | 17 (42.5) | 1 (2.9) |
| Neutropenia | ||||||
| Patients aged < 60 years | 371 (37.5) | 455 (52.8) | 346 (45.3) | 136 (43.5) | 74 (29.7) | 20 (8.7) |
| Patients aged 60 to 64 years | 139 (56.7) | 106 (52.0) | 79 (44.1) | 37 (47.4) | 18 (36.7) | 2 (5.0) |
| Patients aged > 64 years | 91 (55.2) | 97 (65.5) | 61 (48.4) | 17 (43.6) | 11 (33.3) | 1 (3.2) |
| Febrile neutropenia | ||||||
| Patients aged < 60 years | 140 (9.3) | 9 (1.0) | 19 (2.5) | 14 (4.5) | 0 (0.0) | 0 (0.0) |
| Patients aged 60 to 64 years | 30 (11.3) | 1 (0.5) | 5 (2.8) | 4 (5.1) | 3 (6.4) | 0 (0.0) |
| Patients aged > 64 years | 24 (14.3) | 2 (1.4) | 1 (0.8) | 2 (5.1) | 0 (0.0) | 0 (0.0) |
Data presented as n (%). All percentage values are valid. TAC, docetaxel/doxorubicin/cyclophosphamide; ATdd, doxorubicin/docetaxel dose-dense.